Articles By Jack Cush, MD
Limited Counseling for Increased Sodium Intake in the U.S.
Increased sodium intake has been shown to increase Th17 cell activity, and in animal models high-salt diets have been shown to drive IL-23-dependent TH17 cells to cause experimental allergic encephalomyelitis (citation source (http://url.ie/z238). I
Read Article
Adalimumab Drug Levels Predict Efficacy
In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237).
Read Article
Half of US Women are Overweight during Pregnancy
Obesity is associated with adverse outcomes in pregnancy, especially with higher rates of infertility and miscarriage.
Read Article
The Unproven Use of Stem Cell Therapy in OA of the Knee
Regenerative medicine and the use of bone marrow stromal cells (or mesenchymal stem cells - MSC) is controversial in many areas of medicine, including osteoarthritis. MSC use is at a very early stage in orthopedic research, but has been investigated in osteoarthritis of the kn
Read Article
Obesity Drives Rheumatoid Arthritis
Systematic review of the literature examined whether obesity is associated with a higher risk of rheumatoid arthritis (citation source http://url.ie/z1y6) and found that obese individuals (BMI > 30) are at
Read Article
Across the Table: Cush & Schwartzman on Uveitis
In this edition of “Across the Table”, Drs. Cush and Schwartman discuss uveitis. Our expert, Dr. Sergio Schwartzman offers up his approach to diagnosis and management.
Read Article
TNF inhibitors in Early Axial SpA Spares NSAID Use
In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).
Read Article
Ustekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results
615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.
Read ArticleThe Obfuscation of Fibromyalgia
What is going on in the wide and wacky world of pain and fatigue? What use to be called fibromyalgia is being reclassified as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease. Although fibromyalgia has many faces, it does not deserve many names.
Read Article
Ustekinumab Bests TNF Inhibitors for Biologic Survival in Psoriasis
Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv
Read Article
